ArcticZymes launches two new polymerase enzymes

(Tromsø 20. December 2017) Biotec Pharmacon ASA’s (OSE:BIOTEC) subsidiary ArcticZymes has today launched two new polymerase enzymes ArcticZymes entered the polymerase market in September 2016 with its first IsoPolTM enzyme. Today ArcticZymes launches two new polymerase enzymes to complement its expanding IsoPolTM product line of novel polymerases. The new enzymes, IsoPol™ SD⁺ and IsoPol™ BST⁺, … Continued ›

Woulgan listed on UK Drug Tariff from 1 December 2017

Woulgan’s listing on UK Drug Tariff has been brought forward by one month from January 1st 2018 to December 1st 2017 with a reimbursement price of 20 GBP. -We can now actively market the product in both community and in hospital settings, promoting Woulgan with healthcare personnel to try and get their own experience with … Continued ›

Woulgan® to be listed on UK Drug Tariff

Biotec Pharmacon’s wholly owned subsidiary Biotec BetaGlucans has received feedback from the NHS that Woulgan® will be listed on the UK Drug Tariff from January 2018. -This is a key milestone for us because it gives Woulgan access to a major European market. It is also a strong signal to other markets because an objective … Continued ›

ArcticZymes new product launch to serve the bio-manufacturing market segment

Biotec Pharmacon ASA’s subsidiary ArcticZymes has today launched its SAN HQ ELISA immunoassay product which is targeted towards the bio-manufacturing market. ArcticZymes business has largely focused on serving the molecular biology and diagnostics markets. Serving the bio-manufacturing market is a new direction for ArcticZymes in its efforts to expand into other relevant segments. Through its … Continued ›

Biotec has entered into a supply agreement for M-Glucan to the pet sector

Biotec Pharmacon ASA’s subsidiary Biotec BetaGlucans has today signed a supply agreement for M-Glucan™ to a customer within the pet food segment Deliveries under the agreement will commence in the fourth quarter of 2017 and run through 2020. Expected revenues for the contract period is around NOK 3 million depending on customer sales of pet … Continued ›

Biotec Pharmacon appoints new CEO

Biotec Pharmacon ASA is pleased to announce that the company has hired Mr. Christian Jørgensen as the new CEO of Biotec Pharmacon ASA. Christian has a MBA from INSEAD and MSc. Econ. from the University of Copenhagen. He has extensive background from the global healthcare industry, with positions as General Manager for Baxter Healthcare in … Continued ›

Woulgan® application to be reconsidered by UK Drug Tariff

Biotec Pharmacon’s wholly owned company Biotec Betaglucans has received positive feedback from the UK drug tariff appeal panel. They will reconsider Biotec’s application for reimbursement of Woulgan. -We are pleased that the appeal panel concluded positively on our appeal. The application will now return to UK Drug Tariff for a further review. The reason for … Continued ›

Biotec has prolonged supply agreement for delivery of M-Glucan

Biotec Pharmacon ASA’s subsidiary Biotec BetaGlucans AS has today prolonged a supply agreement with an existing feed customer for deliveries of its beta-glucan product M-Glucan® for use in animal health Deliveries under the agreement will continue from this day and run until 30th June 2018 with 6 months renewal option. Expected revenues for the first … Continued ›

Biotec has entered into a supply agreement for M-Gard® in the USA

Biotec Pharmacon ASA’s subsidiary Biotec BetaGlucans has today signed a Term Sheet to supply M-Gard® to a US customer for consumer health applications Biotec BetaGlucans AS has signed a Term Sheet agreement to enter into a business relationship with a US-company, for deliveries of its M-Gard®-ingredient for use in their consumer health products. Deliveries will … Continued ›

Capital Markets Day 2017

Biotec Pharmacon ASA (“Biotec”, OSE: BIOTEC) announces today the company´s strategic update and 2020 ambitions at Biotec´s Capital Markets Day 2017 (CMD). The company is currently building revenues in 4 different markets with a 2020 revenue ambition of NOK 150-200 million where partnerships and value creating activities will be key priorities. – Biotec has over … Continued ›

Browse archive